C-JRLQEnclear Therapies
CSF delivery, precision dosing, neurotechnology
clearingdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JRLQ
C-JRLQC-JRLQCSF delivery, precision dosing, neurotechnology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
EnClear Therapies states that it aims to improve and extend the lives of patients with central nervous system diseases by using its CSF Health Platform for precision dosing. The company presents a belief that closed-loop CSF control combined with integrated ML/AI can deliver CNS therapeutics to the areas most likely to benefit, achieve efficacious drug levels, and reduce severe side effects and peripheral toxicity, with an initial focus on neuro-oncology and later expansion through partnerships into neurodegenerative, lysosomal storage, and autoimmune diseases.
SourceEnClear Therapies states that neurodegenerative diseases can be addressed with device-based therapeutic systems that act on cerebrospinal fluid by continuously recirculating CSF and removing toxic proteins believed to drive disease pathology, with the goal of improving and extending the lives of genetically defined patient populations through advances in biomedical science and engineering.
SourceEnClear Therapies states that cerebrospinal fluid (CSF) can be accessed, recirculated, and modified to improve treatment for central nervous system disease, especially by removing toxic factors in CSF linked to neurodegenerative disease progression and by enabling continuous localized therapeutic delivery and monitoring for more effective, personalized care.
SourceEnClear Therapies presents neurodegenerative disease as an area with no cures, where patients suffer progressive degeneration and death of nerve cells, and states that it is working with partners to help these patients by optimizing the dosage profiles of siRNA and ASO therapies through its CNS-focused delivery platform.
Source